# The Efficacy and Safety of Tocilizumab for Severe RP-ILD Secondary to Systemic Diseases

> **NCT05181397** · PHASE2 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 68 (estimated)

## Conditions studied

- Rapid Progressive Interstitial Lung Diseases

## Interventions

- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT05181397
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-22
- **Primary completion:** 2022-09-01
- **Final completion:** 2022-09-01
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2022-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05181397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05181397, "The Efficacy and Safety of Tocilizumab for Severe RP-ILD Secondary to Systemic Diseases". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05181397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*